

Guest Editorial

THE ROSY AND NOT TOO ROSY EFFECTS OF OMEGA-3 FATTY ACIDS' INTAKE

Lokuruka MNI^{1*}



Michael Lokuruka

*Corresponding author email: mlokuruka@karu.ac.ke and mlokuruka@gmail.com

Michael N.I. Lokuruka, EBS, Department of Food Science and Nutrition, Karatina University, Box 1957-10101, Karatina, Kenya



The omega-3 fatty acids are some of the most talked about nutrients in human nutrition, currently. While we desire to experience optimal well-being from the intake of the recommended levels of the omega 3 fatty acids, their excessive consumption can result in some undesirable effects, just as there are also unpleasant effects from the intake of low amounts in diets, such as dry scaly skin. However, their normal levels in diets pose no risks on human nutrition and metabolism. Some information regarding these health-acclaimed nutrients is as follows:

What are Omega-3 Fatty Acids?

Foods are made up of lipids, among which are fatty acids. The main dietary fatty acids (FA) include saturated fatty acids (SAFA), monounsaturated fatty acids (MUFA) and the polyunsaturated fatty acids (PUFA). Among the PUFA, the omega-3 and omega-6 fatty acids are of interest in this article, though the discussion will focus mainly on the omega-3 FA, but with occasional mention of the roles of the omega-6 FA in human health. Linoleic acid, linolenic acid, alpha linolenic acid (ALA), arachidonic acid (AA), eicosapentaenoic acid (EPA), decosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) are long chain PUFA, with the latter 3 often being referred to as the marine omega-3 FA. ALA is the most common plant-based and diet-derived omega-3 FA and also the main omega-3 FA in vegan diets. Gamma linoleic acid (GLA), linoleic acid (LA), and conjugated linoleic acid (CLA) are omega-6 FA.

Sources of the Omega-3 FA

Fish muscle, fish oils, nuts (especially walnuts), flaxseed and flaxseed oil, and leafy vegetables are good sources of omega-3 FA, with the type in plant foods being ALA [1]. Small amounts of ALA are found in beef from grass-fed ruminants. EPA, DHA and DPA are found naturally in krill, fish and fish oils, such that they are referred to as the marine omega-3 FA. Edible oils from sunflower seed, peanut, maize grain and palm nuts are excellent sources of the omega-6 FA, but they also contain small amounts of ALA. Although ALA is convertible to EPA, the conversion process is inefficient [2]. Algae and seaweed are excellent sources of omega-3 FA as ALA [3]. The amount of EPA and DHA in seafood and in supplements varies, depending for the latter, on the manufacturing process [4]. Different fish species contain varying amounts of the omega-3 fatty acids, with anchovies, salmon, sardines containing > 1,200 mg/100 g of cooked edible portion, while trout and swordfish contain approximately 400-500 mg/100 g of edible portion; the common aquaculture fishes of the tropics such as tilapia and catfish, sea fishes such as the groupers, Mahi Mahi, cod, halibut and haddock, contain less than 250 mg/100 g of cooked edible portion [1]. The low omega-3 FA content in aquaculture-produced fish is due to the inclusion of a high proportion of grain in fish feeds. Consuming less than the 100 g of edible portion of these tropical fish

or no fish at all, may require that one seeks supplementation, though mixed diets may just supply the required amounts of the omega-3 FA. Breast milk contains significant amounts of DHA [5], and is therefore a crucial source of the nutrient for babies. Commercially-prepared and fried fish such as that from restaurants and fast food establishments, should not be relied upon as the main source of the omega-3 FA, as they tend to be relatively lower in them and high in trans-fatty acids due to the high temperature of frying, which destroys the FA and alters their profiles [6], which may affect their bioavailability.

Benefits of Consumption of Omega-3 FA

Unfortunately, the typical modern diet for most societies, often contains more omega-6 than omega-3 FA. This is due to the common use of high omega-6 FA vegetable oils such as sunflower, maize and palm for cooking and baking, resulting in adverse changes in the omega-3 to omega-6 FA ratio. Low omega-3 diets may also adversely upset the ratio of the two FA. As the average human diet therefore provides adequate omega-6 FA, supplementation is not generally necessary for this class of FA. As both omega-3 and 6 FA play important roles in human health, it is important to keep the two balanced. Health experts and authorities recommend the ratio of omega-6 to omega-3 FA in a healthy diet should be 4:1 [7], though a recent study indicates a lower ratio is healthier and more protective against disease [8]. Advice to increase the ratio of the two FA should target an increase in the dietary intake of the omega-3 FA from fish and other seafood, rather than lowering the intake of the omega-6 FA [9]. It has been shown that the ratio of 20:1 (omega-6: omega-3) is common in American diets [10], with the indication that the ratio is similar or higher in most other parts of the world [11] in studies of red blood cell omega-3 index (O3I). The resulting imbalance of omega-6 to omega-3 FA has been suggested to contribute to a higher risk of developing various health problems, such as heart disease [12], cancer [13], asthma [14], arthritis [15] and depression [16]. But, specifically, the higher ratio favours atherosclerotic plaque inflammation [17], which is a trigger of high-risk cardiovascular disease (CVD) events [18], and also leads to poor brain development and function [19]. Though regarded generally as beneficial in CVD amelioration, there is controversial evidence regarding the effects of omega-6 PUFA on CVD risk. Despite the beneficial impact of omega-6 PUFA supplementation on CVD outcomes being supported by some studies, other studies report conflicting results [20, 21]. One plausible mechanism that may explain the relationship between omega-6 PUFA and CVD is the increased production of 2-series prostaglandins and 4-series leukotrienes due to the high content of omega-6 PUFA in the diet, exerting pro-inflammatory effects and thus potentiating CVD risk [20, 21]. Highly unsaturated FA such as AA appear to be linked to an increase in low-density lipoprotein cholesterol (LDL-C) and very-low density lipoprotein (VLDL)

susceptibility to oxidation, thus enhancing their atherogenic effect [20]. Also, some studies found no association between omega-6 PUFA intake and CVD risk. In the Sydney Diet Heart Study, a randomized control trial (RCT) of 458 participants aged 30–59 years with a recent coronary event, the replacement of SAFA with LA (an omega-6 FA) significantly increased all-cause mortality [22]. Also, a meta-analysis of 32 observational studies and 27 RCTs reported no correlation between omega-6 PUFA supplementation and coronary heart disease (CHD) [23].

Studies in pre-term and full-term infants suggest that getting enough omega-3 FA in the diet of the mother is essential for optimal visual development (eye and optic nerve development). Several studies have also shown that animals that do not get enough DHA in their diets, suffer visual impairment and degradation of the retina [24, 25], though one 2-year long, controlled study, recently showed this may be beneficial only in the early stages of loss of retinal integrity and disease onset [26]. Human studies have also shown that low levels of DHA and EPA are found in diabetic retinopathy, age-related macular degeneration (ARMD), dry eye disease (DED) and retinopathy of prematurity [25, 27], thus pointing to the important role that adequate levels of DHA and EPA play in retinal health and prevention of ocular dystrophies. Thus, chronic inflammation may play a role in the development of many common, degenerative and potentially devastating eye conditions, but specifically, the omega-3 FA seem to play a key role in the body's ability to regulate and balance inflammation. Over the 12 years that participants were followed in the landmark AREDS study (Age-Related Eye Disease Study), conducted by the US National Eye Institute, those that reported the highest intake of omega-3 FA in their diets, were 30% less likely to develop central geographic atrophy or wet ARMD [28].

It seems that omega-3 intake by an expectant mother is essential for brain and eye (neurological and visual) development of the foetus [19]. As omega-3 FA are significant components of breast milk, they may be necessary for infant nutrition and healthy development [29] as research has established that the addition of EPA and DHA to the diet of pregnant women, has a positive effect on visual and cognitive development of the baby [30]. However, Guillot *et al.* [31], showed that maternal DHA supplementation did not improve neurodevelopmental outcomes at 18 to 22 months' gestational age in breastfed, preterm neonates, though subgroup analyses in the same study suggested a potential benefit for language acquisition in preterm neonates born before 27 weeks' gestational age. Strømme *et al.* [32], also found that enhanced nutrient supply to very low birth weight infants (<1,500 g birth weight), resulted in improved white matter maturation and head growth, thus implying some benefits of the omega-3 FA to the neonate.

Some Not too Rosy Effects of Omega-3 FA intake as Supplements

High doses of the omega-3 FA >2,000 mg, but less than 4,000 mg/day, are generally regarded to be safe and are well tolerated, though there are reported adverse effects of their consumption as supplements [33, 34, 35]. A recent, systematic review of RCTs published between 1987 and 2023 concluded that the adverse effects of omega-3 PUFA containing EPA or DHA, or both, compared with controls (a placebo or a standard treatment), had significantly higher odds of occurrence of diarrhoea, dysgeusia, and bleeding tendency, but lower rates of back pain [35]. The most common and significant side effects of excessive supplement intake are gastrointestinal (e.g., nausea and bloating), dermatological (skin itching), and haematological (anticoagulatory effects) [33]. Other reported side effects of high dose consumption of the omega-3 FA in clinical trials, included increased bleeding risk [36], increased LDL-C production (though it increased LDL density) [37], and the inability to control blood sugar levels [38], meaning that there would be no benefit of omega-3 FA supplementation for diabetic patients. Other risks associated with excessive intake of supplemental omega-3 PUFA include altered platelet function and the potential for lipid peroxidation. Long-chain, highly unsaturated fatty acids such as EPA and DHA, are at high risk of peroxidation. Membrane phospholipid fatty acids can be vulnerable to peroxidation, resulting in free radical formation, which can be detrimental to proteins and DNA integrity [33]. However, in a study (though short), on young horses fed 60 mg/Kg of body weight daily for 60 days, omega-3 FA supplements did not negatively affect Vitamin E status or promote lipid peroxidation [39]. Nonetheless, systematic reviews that examined the safety profile of omega-3 FA, when doses of up to 4,000 mg/day were consumed, concluded that supplementation is well tolerated and that associated adverse events were of no clinical significance [40]. All in all, potential risks of omega-3 FA intake, should be assessed versus the potential benefits, with the adverse effects likely to be dose-dependent. Also, most side effects are apparent only with the intake of supplements, as the amounts of the omega-3 FA in diets are normally low, with amounts varying depending on the nature of the food and manner of processing. To avoid undesirable side effects, consumers should eat as much of the plant sources of omega-3 FA, as any adverse side effects from their consumption are minimal. The time at high temperature processing of food should be kept short in order to maximize dietary omega-3 retention and therefore their intake.

Conclusion and Recommendations for Development

Omega-3 FA include EPA, DHA and DPA, which are commonly referred to as the marine omega-3 FA, and, ALA being the plant-based type. Although ALA is convertible to EPA, the metabolic process is inefficient. Wild fish, fish oils, krill, microalgae and algal oils are the best sources of the omega-3 FA, with walnuts, flax seeds and flax seed oil being good



plant sources of the FA, but as ALA. To improve health outcomes, health authorities recommend the intake of 1,000-2,000 mg/day of supplements as safe, though amounts of up to 4,000 mg/day can be tolerated.

Most adverse effects of the excessive intake of omega-3 FA are apparent only with the intake of supplements as amounts of the omega-3 FA in diets are normally low, with amounts varying depending on the nature of food and manner of processing. The significant and adverse effects include gastrointestinal (nausea and bloating), dermatological (skin itching), and haematological (anticoagulatory). Other uncommon adverse effects include bleeding risk, increased LDL-C production, the inability to control blood sugar levels and altered platelet function.

To minimize and avoid undesirable side effects, consumers should eat mainly plant sources of omega-3 FA. To reduce the generation of trans fatty acids from high temperature thermal fish processing and retain as much of the omega-3 FA, broiling, baking or grilling instead of frying are recommended. For individuals who do not eat fish, EPA, DHA and DPA, are manufactured commercially from microalgae and algal oil for their use. To improve the blood serum omega-3 index to $\geq 8\%$, the consistent and habitual intake of 1,000-1,500 mg/day for at least 12 weeks is recommended.



REFERENCES

1. **Hughes CL and TR Dhiman** Dietary compounds in relation to dietary diversity and human health. *J. Med. Food.* 2002; **5(2)**: 51–68.
2. **Baker EJ, Miles EA, Burdge GC, Yaqoob P and PC Calder** Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. *Prog. Lipid Res.* 2016 Oct; **64**: 30-56. <https://doi.org/10.1016/j.plipres.2016.07.002>
3. **Borowitzka MA** High-value products from microalgae-their development and commercialisation. *J. Appl. Phycol.* 2013; **25**: 743–756. <https://doi.org/10.1007/s10811-013-9983-9>
4. **Wang H and BP Daggy** The role of fish oil in inflammatory eye diseases. *BioMed. Hub J.* 2017; **2(1)**: 1-12. <https://doi.org/10.1159/00045581846>
5. **Bzikowska-Jura A, Czerwonogrodzka-Senczyna A, Jasińska-Melon E, Mojska H, Olędzka G, Wesołowska A and D Szostak-Węgierek** The Concentration of Omega-3 Fatty Acids in Human Milk Is Related to Their Habitual but Not Current Intake. *Nutrients* 2019 Jul. 12; **11(7)**: 1585. <https://doi.org/10.3390/nu11071585>
6. **American Heart Association Nutrition Subcommittee; Council on Cardiovascular Nursing and Council on Epidemiology and Prevention.** American Heart Association Science Advisory Omega-6 fatty acids and risk of cardiovascular disease. *Circulation.* 2009; **119**: 0-0.
7. **Meng L** How fish is cooked affects heart-health benefits of omega-3 fatty acids. American Heart Association (AHA), Scientific Conference, Hawaii, Manoa, 2009
8. **Kris-Etherton PM and S Innis** Position of the American Dietetic Association and Dietitians of Canada: Dietary fatty acids. *J. Am. Diet Assoc.* 2007; **107**: 1599-1611.
9. **American Heart Association Nutrition Committee.** Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. *Circulation* 2006; **114**: 82-96.
10. **DiNicolantonio JJ and J O'Keefe** Importance of maintaining a low omega-6/omega-3 ratio for reducing platelet aggregation, coagulation and thrombosis. *Open Heart* 2019 May 2; **6(1)**: e001011. <https://doi.org/10.1136/openhrt-2019-001011>



11. **Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF and RR Rawlings** Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. *Am. J. Clin. Nutr.* 2011 May; **93(5)**: 950-62. <https://doi.org/10.3945/ajcn.110.006643>
12. **Stark KD, Van Elswyk ME, Higgins MR, Weatherford C and N Salem Jr** Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. *Progress Lipid Res.* 2016; **63**: 132-152.
13. **Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, Thompson IM, King IB, Albanes D and AR Kristal** Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. *Am. J. Epidemiol.* 2011 Jun 15; **173(12)**: 1429-39. <https://doi.org/10.1093/aje/kwr027>
14. **Reisman J, Schachter HM, Dales RE, Tran K, Kourad K, Barnes D, Sampson M, Morrison A, Gaboury I and J Blackman** Treating asthma with omega-3 fatty acids: where is the evidence? A systematic review. *BMC Complement Altern. Med.* 2006 Jul 19; **6**: 26. <https://doi.org/10.1186/1472-6882-6-26>
15. **Kostoglou-Athanassiou I, Athanassiou L and P Athanassiou** The Effect of Omega-3 Fatty Acids on Rheumatoid Arthritis. *Mediterr J Rheumatol.* 2020 Jun 30; **31(2)**: 190-194. <https://doi.org/10.31138/mjr.31.2.190>
16. **Wani AL, Bhat SA and A Ara** Omega-3 fatty acids and the treatment of depression: a review of scientific evidence. *Integr. Med. Res.* 2015; **4(3)**: 132-141. <https://doi.org/10.1016/j.imr.2015.07.003>
17. **Cawood A, Ding R, Napper FL, Young RH, Williams JA, Ward M.J, Gudmundsen O., Vige R., Payne SP and S Ye S, Shearman CP, Gallagher PJ, Grimble RF and PC Calder** Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. *Atherosclerosis.* 2010; **212**: 252–259. <https://doi.org/10.1016/j.atherosclerosis.2010.05.022>

18. **Nicholls SJ., Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJ, Koenig W and DK McGuire** Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial. *JAMA*. 2020; **324**: 2268–2280 <https://doi.org/10.1001/jama.2020.22258>
19. **Mallick R, Basak S and AK Duttaroy** Docosahexaenoic acid, 22:6n-3: Its roles in the structure and function of the brain. *Int. J. Developmental NeuroScience* 2019; <https://doi.org/10.1016/j.ijdevneu.2019.10.004>
20. **Russo GL** Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. *Biochem. Pharmacol.* 2009; **77**: 937–46.
21. **Siriwardhana N, Kalupahana NS, Fletcher S, Xin W, Claycombe KJ, Quignard-Boulange A, Zhao L, Saxton AM and N Moustaid-Moussa** n-3 and n-6 polyunsaturated fatty acids differentially regulate adipose angiotensinogen and other inflammatory adipokines in part via NF-κ B-dependent mechanisms. *J. Nutr. Biochem.* 2012 Dec; **23**(12): 1661-7. <https://doi.org/10.1016/j.jnutbio.2011.11.009>
22. **Ramsden CE, Zamora D, Leelarthapin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, Ringel A, Davis JM and JR Hibbeln** Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. *BMJ* 2013 Feb 4; **346**: e8707. <https://doi.org/10.1136/bmj.e8707>
23. **Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, Khaw KT, Mozaffarian D, Danesh J and E DiAngelantonio** Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. *Ann. Intern. Med.* 2014 Mar 18; **160**(6): 398-406. <https://doi.org/10.7326/M13-1788>
24. **Swinkels D and M Baes** The essential role of docosahexaenoic acid and its derivatives for retinal integrity. *Pharmacol Ther.* 2023 Jul; **247**: 108440. <https://doi.org/10.1016/j.pharmthera.2023.108440>

25. **Weir N, Guan W, Karger AB, Klein BEK, Meuer SM, Cotch MF, Guo X, Li X, Tan J, Genter P, Chen YI, Rotter JI, Ipp E and MY Tsai** Omega-3 Fatty Acids are Associated with Decreased Presence and Severity of Diabetic Retinopathy: A Combined Analysis of MESA and GOLDR Cohorts. *Retina* 2023 Jun 1; **43(6)**: 984-991. <https://doi.org/10.1097/IAE.0000000000003745>
26. **García P, Hernández Martínez FJ, Aznárez López N, Castellón Torre L and ME Tena Sempere** Supplementation with a Highly Concentrated Docosahexaenoic Acid (DHA) in Non-Proliferative Diabetic Retinopathy: A 2-Year Randomized Double-Blind Placebo-Controlled Study. *Antioxidants* (Basel). 2022 Jan 5; **11(1)**: 1-16. <https://doi.org/10.3390/antiox11010116>
27. **Sugasini D, Yalagala PCR and PV Subbaiah** Efficient Enrichment of Retinal DHA with Dietary Lysophosphatidylcholine-DHA: Potential Application for Retinopathies. *Nutrients* 2020 Oct 12; **12(10)**: 3114. <https://doi.org/10.3390/nu12103114> Erratum in: *Nutrients*. 2021 Jun 24; **13(7)**. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601701/>
28. **Sangiovanni JP, Agron E, Meleth AD, Reed GF, Sperduto RD, Clemons TE, Emily YC and Age-Related Eye Disease Study Research Group** ω -3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study. *Am. J. Clin. Nutr.* 2009; **90**: 1601-7. <https://www.ncbi.nlm.nih.gov/pubmed/19812176>
29. **Mosca F and ML Gianni** Human milk: Composition and health benefits. *Pediatr. Med. Chir.* 2017; **39**: 155. <https://doi.org/10.4081/pmc.2017.155>
30. **Delgado-Noguera MF, Calvache JA and X Bonfill-Cosp** Supplementation with long chain polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child growth and development. *Cochrane Database Syst. Rev.* 2010: Cd007901. <https://doi.org/10.1002/14651858.CD007901.pub2>
31. **Guillot M, Synnes A, Pronovost E, Qureshi M, Daboval T, Caouette G, Olivier F, Bartholomew J, Mohamed I, Massé E, Afifi J, Henderson L, Lemyre B, Luu TM, Strueby L, Cieslak Z, Yusuf K, Pelligra G, Ducruet T, Khairy AB, Ndiaye T, Angoa G, Sériès T, Piedboeuf B, Nuyt AM, Fraser W, Mâsse B, Lacaze-Masmonteil T, Lavoie PM and I Marc** Maternal High-Dose DHA Supplementation and Neurodevelopment at 18–22 Months of Preterm Children. *Pediatrics* 2022; **150(1)**: e2021055819. <https://doi.org/10.1542/peds.2021-055819>



32. **Strømmen K, Blakstad EW, Moltu SJ, Almaas AN, Westerberg AC, Amlien IK and PO Iversen** Enhanced nutrient supply to very low birth weight infants is associated with improved white matter maturation and head growth. *Neonatology* 2014; **107**(1): 68-75.
33. **Wander RC, Hall JA, Gradin JL, Shi-Hua Du and DE Jewell** The Ratio of Dietary (n-6) to (n-3) Fatty Acids Influences Immune System Function, Eicosanoid Metabolism, Lipid Peroxidation and Vitamin E Status in Aged Dogs. *J. Nutr.* 1997; **127**(6): 1198-1205.
<https://doi.org/10.1093/jn/127.6.1198>
34. **Wensing AG, Mensink RP and G Hornstra** Effects of dietary n-3 polyunsaturated fatty acids from plant and marine origin on platelet aggregation in healthy elderly subjects. *Br. J. Nutr.* 1999; **82**: 183–191.
35. **Jane Pei-Chen Chang, Ping-Tsao Tseng, Bing-Syuan Zeng, Cheng-Ho Chang, Huanxing-Su, Po-Han Chou and Kuan-Pin Su** Safety of supplementation of omega-3 polyunsaturated fatty acids: a systematic review and meta-analysis of randomized controlled trials. *Adv. Nutr.* 2023; **14**(6): P1326-P1336. <https://doi.org/10.1016/j.advnutr.2023.08.003>
36. **Bhatt DL, P. Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB and RT Doyle Jr.** for the REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *New Eng. J. Med.* 2019; **380**(1): 11-22. <https://doi.org/10.1056/NEJMoa1812792>
37. **Calabresi DD, Pazzucconi F, Sirtori CR and G Franceschini** Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. *Atherosclerosis* 2000 Feb; **148**(2): 387-96.
[https://doi.org/10.1016/s0021-9150\(99\)00267-1](https://doi.org/10.1016/s0021-9150(99)00267-1)
38. **Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S and J Armitage** ASCEND Study Collaborative Group; Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. *New Engl. J. Med.* 2018 Oct 18; **379**(16): 1540-1550. <https://doi.org/10.1056/NEJMoa1804989>

39. **White-Springer SH, Vineyard KR, Kivipelto J and LK Warren** Dietary omega-3 fatty acid supplementation does not impair vitamin E status or promote lipid peroxidation in growing horses. *J. Anim. Sci.* 2021 Jul 1; **99(7)**: skab177. <https://doi.org/10.1093/jas/skab177>
40. **Dighriri IM, Alsubaie AM, Hakami FM, Hamithi DM, Alshekh MM, Khobrani FA, Dalak FE, Hakami AA, Alsueaadi EH, Alsaawi LS, Alshammari SF, Alqahtani AS, Alawi IA, Aljuaid AA and MQ Tawhari** Effects of Omega-3 Polyunsaturated Fatty Acids on Brain Functions: A Systematic Review. *Cureus.* 2022 Oct 9; **14(10)**: e30091. <https://doi.org/10.7759/cureus.30091>